Maridebart Cafraglutide — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Maridebart Cafraglutide

Also known as: AMG 133, MariTide

Antibody-peptide conjugate; GLP-1 receptor agonist / GIP receptor antagonist (bispecific)

Research chemicalLast updated: October 19, 2026Based on 7 peer-reviewed studies

What it is

Maridebart cafraglutide is an experimental weight-loss drug in clinical trials for obesity. It activates the GLP-1 pathway that curbs appetite while simultaneously blocking a second signal that promotes fat storage. Not FDA-approved; Phase 2 trials ongoing; early data show strong weight-loss results.

The scientific side

Maridebart cafraglutide (AMG 133) is a long-acting bispecific peptide-antibody conjugate engineered by conjugating a fully human monoclonal anti-human GIP receptor (GIPR) antagonist antibody to two GLP-1 analogue agonist peptides via amino acid linkers. It simultaneously activates GLP-1 receptors (GLP-1R agonism) and blocks GIP receptors (GIPR antagonism), combining complementary mechanisms of action in a single molecular entity. This dual mechanism is intended to enhance weight loss and improve metabolic parameters; both GIPR agonism (as in tirzepatide) and GIPR antagonism (as in maridebart cafraglutide) have paradoxically shown additive weight loss effects when combined with GLP-1R agonism (PMID 40507574, PMID 42166683). The antibody scaffold extends the plasma half-life beyond that of peptide-only approaches, enabling once-monthly subcutaneous dosing (PMID 42592044, PMID 40549887).

Class: Antibody-peptide conjugate; GLP-1 receptor agonist / GIP receptor antagonist (bispecific)

Administration & storage

Administration
Subcutaneous injection (PMID: 40549887)
Storage
Storage conditions for maridebart cafraglutide are not described in the reviewed abstracts.
Cautions
Gastrointestinal adverse events were common with maridebart cafraglutide in the phase 2 trial; they were less frequent with dose escalation and lower starting doses.,Maridebart cafraglutide is currently in clinical trial phases only; it is not an approved drug. Self-administration outside of supervised clinical study settings carries unknown risks.,No long-term human safety data beyond 52 weeks are reported in the reviewed abstracts. Long-term metabolic impacts of GIPR antagonism remain to be established.,Preclinical data indicated that GIPR antagonism reduced insulin sensitivity compared to pair-fed controls and reduced expression of adipose tissue lipolytic genes in obese male mice.,Sterile technique is essential for any subcutaneous injection to prevent infection.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification